Partner with Us

Partnership Opportunities

Syros is dedicated to developing therapies that control gene expression with the aim of providing a profound and durable benefit for patients.

Our lead program, tamibarotene, an oral, selective retinoic acid receptor alpha agonist, is currently being evaluated in a pivotal Phase 3 trial in a genomically defined subset of patients with myelodysplastic syndrome for which pivotal data are expected by mid-Q4 2024, and in a randomized Phase 2 trial in a genomically defined subset of patients with AML for which encouraging data were reported in December 2023. We hold exclusive development and commercial rights to tamibarotene for cancer indications in the Americas, Europe, Australia and Israel. We are exploring partnership opportunities to develop and commercialize tamibarotene in the territories outside the United States.

Additionally, we have worldwide rights for SY-5609, an oral reversible inhibitor of CDK7 with best-in-class selectivity and potency, and we are seeking global out-license opportunities for further development.

Contact us at to learn more about partnership opportunities.

We Are Committed to Developing New Standards of Care

We are driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, and aim to develop new standards of care for the frontline treatment of patients with hematologic malignancies.

View Our Programs

A Platform Solely Focused on Gene Control

We have used our gene control platform to analyze regulatory regions of the genome to systematically and efficiently identify disease-causing alterations in gene expression with broad potential to create transformative medicines.

View Our Platform